| 30/09/26 | 13:00:00 | 30 Sept 2026 | | Interim Results for the Six Months to June 30, 2026, and Business Update | GNW |
| 25/09/26 | 07:00:00 | 25 Sept 2026 | | The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer | GNW |
| 16/09/26 | 16:00:00 | 16 Sept 2026 | | Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial | GNW |
| 14/09/26 | 07:00:00 | 14 Sept 2026 | | Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee | GNW |
| 08/07/26 | 07:00:00 | 8 Jul 2026 | | Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors | GNW |
| 01/06/26 | 07:00:00 | 1 Jun 2026 | | Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 | GNW |
| 19/05/26 | 07:14:00 | 19 May 2026 | | Unaudited Preliminary Results for the Year Ended December 31, 2025 | GNW |
| 06/05/26 | 07:00:00 | 6 May 2026 | | Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 | GNW |
| 21/04/26 | 17:00:00 | 21 Apr 2026 | | Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform | GNW |
| 16/09/24 | 07:00:07 | 16 Sept 2024 | | Avacta Reported Updated Phase 1 Data of AVA6000 | RNS |
| 12/09/24 | 07:00:13 | 12 Sept 2024 | | Notice of Results | RNS |
| 09/09/24 | 07:00:07 | 9 Sept 2024 | | Avacta to present clinical data at ESMO Congress | RNS |
| 02/09/24 | 15:53:56 | 2 Sept 2024 | | Director/PDMR Shareholdings and TVR | RNS |
| 18/07/24 | 07:00:10 | 18 Jul 2024 | | Convertible Bond Payment | RNS |
| 26/06/24 | 14:46:25 | 26 Jun 2024 | | Result of AGM | RNS |
| 26/06/24 | 07:00:12 | 26 Jun 2024 | | AGM Business Update | RNS |
| 20/06/24 | 07:00:10 | 20 Jun 2024 | | Shaun Chilton appointed Non-Executive Chairman | RNS |
| 11/06/24 | 07:00:10 | 11 Jun 2024 | | Appointment of Nominated Adviser and Sole Broker | RNS |
| 31/05/24 | 07:00:13 | 31 May 2024 | | Posting of Annual Report and Notice of AGM | RNS |
| 23/05/24 | 07:00:13 | 23 May 2024 | | Successful Completion of First Cohort | RNS |
| 30/04/24 | 07:01:00 | 30 Apr 2024 | | Full Year Results | RNS |
| 30/04/24 | 07:00:15 | 30 Apr 2024 | | Board Change | RNS |
| 26/04/24 | 09:51:57 | 26 Apr 2024 | | Block listing Interim Return REPLACEMENT | RNS |
| 26/04/24 | 07:00:12 | 26 Apr 2024 | | Block Listing Six Monthly Return | RNS |
| 23/04/24 | 09:43:05 | 23 Apr 2024 | | Block Listing Application to AIM | RNS |
| 23/04/24 | 07:00:10 | 23 Apr 2024 | | Notice of Results | RNS |
| 22/04/24 | 12:14:55 | 22 Apr 2024 | | Issue of Equity and Total Voting Rights | RNS |
| 09/04/24 | 17:00:00 | 9 Apr 2024 | | Avacta Reports Data at the AACR Annual Meeting | RNS |
| 08/04/24 | 07:00:07 | 8 Apr 2024 | | AVA6000 Abstract Release by AACR | RNS |
| 28/03/24 | 16:00:35 | 28 Mar 2024 | | Investor Webinar | RNS |
| 21/03/24 | 07:00:06 | 21 Mar 2024 | | Update on AVA6000 Phase 1a Clinical Trial Progress | RNS |
| 18/03/24 | 13:26:28 | 18 Mar 2024 | | Result of General Meeting | RNS |
| 06/03/24 | 07:00:09 | 6 Mar 2024 | | Avacta Announces AVA6000 Poster at AACR | RNS |
| 05/03/24 | 07:00:10 | 5 Mar 2024 | | Result of REX Retail Offer | RNS |
| 29/02/24 | 07:00:13 | 29 Feb 2024 | | Result of Placing | RNS |
| 28/02/24 | 16:42:19 | 28 Feb 2024 | | Proposed REX Retail Offer | RNS |
| 28/02/24 | 16:41:25 | 28 Feb 2024 | | Proposed Fundraise to progress Therapeutics | RNS |
| 16/02/24 | 07:00:06 | 16 Feb 2024 | | Share Incentive Plan/Issue of Equity | RNS |
| 22/01/24 | 10:51:02 | 22 Jan 2024 | | Issue of Equity and Total Voting Rights | RNS |
| 19/01/24 | 07:00:03 | 19 Jan 2024 | | Appointment of Christina Coughlin | RNS |
| 19/12/23 | 07:00:11 | 19 Dec 2023 | | Appointment of Chief Business Officer | RNS |
| 13/12/23 | 07:00:16 | 13 Dec 2023 | | ALS-6000-101 Phase 1a Study Data | RNS |
| 04/12/23 | 07:00:04 | 4 Dec 2023 | | Shareholder update to review AVA6000 Phase 1a data | RNS |
| 27/10/23 | 07:00:10 | 27 Oct 2023 | | Block Listing Six Monthly Return | RNS |
| 23/10/23 | 13:30:00 | 23 Oct 2023 | | Issue of Equity and Total Voting Rights | RNS |
| 18/10/23 | 13:00:00 | 18 Oct 2023 | | Block Listing Application to AIM | RNS |
| 05/10/23 | 07:00:03 | 5 Oct 2023 | | Avacta to present at AACR-NCI-EORTC conference | RNS |
| 29/09/23 | 13:30:02 | 29 Sept 2023 | | Director/PDMR Shareholding | RNS |
| 28/09/23 | 07:00:09 | 28 Sept 2023 | | Interim Results for the Period Ending 30 June 2023 | RNS |
| 20/09/23 | 14:00:01 | 20 Sept 2023 | | Issue of Equity and Total Voting Rights | RNS |
